Tenax Therapeutics
TENX
5 hedge funds and large institutions have $1M invested in Tenax Therapeutics in 2013 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
1,644% more capital inflows, than outflows
Capital inflows: $942K | Capital outflows: $54K
400% more funds holding
Funds holding: 1 → 5 (+4)
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
8.93% more ownership
Funds ownership: 1.79% → 10.73% (+8.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$135K |
| 2 |
Ellington Management Group
Old Greenwich,
Connecticut
|
+$135K |
| 3 |
Tower Research Capital (TRC)
New York
|
+$135K |
| 4 |
UBS
Zurich,
Switzerland
|
+$135K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$54K |
TENX Hedge Fund Activity: Q4 2013 in Review
5 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Tenax Therapeutics (TENX) for Q4 2013, worth a combined $1M — up 1,726% from $55K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TENX positions and 1 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Barclays, opening a new position worth an estimated $135K. The largest seller was Sabby Management, exiting entirely with an estimated $54K sold.
- 5 institutional investors held Tenax Therapeutics (TENX) as of Q4 2013, up from 1 in Q3 2013.
- Funds reported $1M of Tenax Therapeutics stock for Q4 2013, up 1,726% quarter-over-quarter.
- 5 funds opened new Tenax Therapeutics positions in Q4 2013 and 1 closed out, a net change of +4 holders.
- The largest Tenax Therapeutics buyer in Q4 2013 was Barclays, an estimated $135K added.
- The largest Tenax Therapeutics seller in Q4 2013 was Sabby Management, an estimated $54K sold.
Based on aggregated 13F filings for Q4 2013.